Rolf Jorde1, Yngve Figenschau. 1. Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway. rolf.jorde@unn.no
Abstract
BACKGROUND: Studies have suggested that vitamin D may be important for both insulin sensitivity and insulin secretion, and that supplementation with vitamin D may subsequently prevent development of type 2 diabetes. AIM OF THE STUDY: The objective of the current study was to test the hypothesis that supplementation with vitamin D would improve glycaemic control in subjects with type 2 diabetes. METHODS:Thirty-six subjects with type 2 diabetes, treated with metformin and bed-time insulin, were randomised to supplementation with cholecalciferol (40,000 IU per week) versus placebo for 6 months. Thirty-two subjects participated throughout the entirety of the study. Fasting blood samples were drawn before and at the end of the 6 month study without the previous bed-time insulin injection. The insulin and metformin doses were not changed throughout the study. RESULTS: After 6 months, the fasting glucose, insulin, C-peptide, fructosamine, and HbA(1c) levels were not significantly different from baseline values. In addition, changes in these parameters (values at 6 months minus values at baseline) did not differ between the vitamin D and the placebo group. CONCLUSIONS: We were not able to demonstrate that vitamin D supplementation had a significant effect on glucose metabolism in subjects with type 2 diabetes but without vitamin D deficiency. Further studies are needed in larger groups of subjects with type 2 diabetes or impaired glucose tolerance, who also exhibit low serum 25-hydroxyvitamin D levels.
RCT Entities:
BACKGROUND: Studies have suggested that vitamin D may be important for both insulin sensitivity and insulin secretion, and that supplementation with vitamin D may subsequently prevent development of type 2 diabetes. AIM OF THE STUDY: The objective of the current study was to test the hypothesis that supplementation with vitamin D would improve glycaemic control in subjects with type 2 diabetes. METHODS: Thirty-six subjects with type 2 diabetes, treated with metformin and bed-time insulin, were randomised to supplementation with cholecalciferol (40,000 IU per week) versus placebo for 6 months. Thirty-two subjects participated throughout the entirety of the study. Fasting blood samples were drawn before and at the end of the 6 month study without the previous bed-time insulin injection. The insulin and metformin doses were not changed throughout the study. RESULTS: After 6 months, the fasting glucose, insulin, C-peptide, fructosamine, and HbA(1c) levels were not significantly different from baseline values. In addition, changes in these parameters (values at 6 months minus values at baseline) did not differ between the vitamin D and the placebo group. CONCLUSIONS: We were not able to demonstrate that vitamin D supplementation had a significant effect on glucose metabolism in subjects with type 2 diabetes but without vitamin D deficiency. Further studies are needed in larger groups of subjects with type 2 diabetes or impaired glucose tolerance, who also exhibit low serum 25-hydroxyvitamin D levels.
Authors: Anastassios G Pittas; Bess Dawson-Hughes; Tricia Li; Rob M Van Dam; Walter C Willett; Joann E Manson; Frank B Hu Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Huicui Meng; Nirupa R Matthan; Edith Angellotti; Anastassios G Pittas; Alice H Lichtenstein Journal: Am J Clin Nutr Date: 2020-09-01 Impact factor: 7.045
Authors: Mansour K Al-Zahrani; Abdulrahman M Elnasieh; Farhan M Alenezi; Abdulrahman A Almoushawah; Mohammed Almansour; Fahad Alshahrani; Saeed Ur Rahman; Abdullah Al-Zahrani Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Jennifer C Seida; Joanna Mitri; Isabelle N Colmers; Sumit R Majumdar; Mayer B Davidson; Alun L Edwards; David A Hanley; Anastassios G Pittas; Lisa Tjosvold; Jeffrey A Johnson Journal: J Clin Endocrinol Metab Date: 2014-07-25 Impact factor: 5.958